Biocon shares gain after US FDA approves cancer drug biosimilar
CNBC-TV18

Biocon shares gained after the US FDA approved its cancer drug biosimilar, with a US launch expected in 2028.
The biosimilar to Perjeta has been approved for patients with metastatic and
early-stage HER2-positive breast cancer. Biocon expects to launch the drug in
the US in Q3 2028 under its licensing agreement with Genentech.





